BACKGROUND: Tamoxifen (TAM) is a selective estrogen receptor modulator (SERM) that is widely used as adjuvant therapy in breast cancer patients; however, it is also associated with undesirable side effects. The goal of this study was to investigate TAM-related side effects, and determine profiles of side effects by race and by smoking status. METHODS: A secondary data analysis was conducted using cross-sectional study data from 138 African American and Caucasian women with breast cancer taking TAM 20mg daily for at least 30 days prior to enrollment. Participants completed questionnaires that obtained information about demographic characteristics, reproductive history, health and lifestyle characteristics, TAM use and its related side effects. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals. RESULTS: Compared to never smokers, a significantly greater percentage of current smokers reported ever experiencing TAM-related nausea (28.0% versus 5.0%, P=0.007), depression (40.0% versus 7.1%, P=0.001) and migraines (19.2% versus 1.7%, P=0.02). These differences remained statistically significant after controlling for race, age, obesity, tumor stage, and duration of TAM treatment. No significant differences by race were noted in women reporting TAM side effects. CONCLUSION: The findings from this study suggest that current smokers with breast cancer should be informed of the increased probability of reporting TAM-related side effects such as nausea, depression and migraines, and counseled about smoking cessation which may reduce the incidence of these side effects.
BACKGROUND:Tamoxifen (TAM) is a selective estrogen receptor modulator (SERM) that is widely used as adjuvant therapy in breast cancerpatients; however, it is also associated with undesirable side effects. The goal of this study was to investigate TAM-related side effects, and determine profiles of side effects by race and by smoking status. METHODS: A secondary data analysis was conducted using cross-sectional study data from 138 African American and Caucasian women with breast cancer taking TAM 20mg daily for at least 30 days prior to enrollment. Participants completed questionnaires that obtained information about demographic characteristics, reproductive history, health and lifestyle characteristics, TAM use and its related side effects. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals. RESULTS: Compared to never smokers, a significantly greater percentage of current smokers reported ever experiencing TAM-related nausea (28.0% versus 5.0%, P=0.007), depression (40.0% versus 7.1%, P=0.001) and migraines (19.2% versus 1.7%, P=0.02). These differences remained statistically significant after controlling for race, age, obesity, tumor stage, and duration of TAM treatment. No significant differences by race were noted in women reporting TAM side effects. CONCLUSION: The findings from this study suggest that current smokers with breast cancer should be informed of the increased probability of reporting TAM-related side effects such as nausea, depression and migraines, and counseled about smoking cessation which may reduce the incidence of these side effects.
Authors: Canhua Xiao; Alexandra Hanlon; Qiang Zhang; Benjamin Movsas; Kian Ang; David I Rosenthal; P Félix Nguyen-Tan; Harold Kim; Quynh Le; Deborah Watkins Bruner Journal: Cancer Date: 2013-12-11 Impact factor: 6.860
Authors: Humberto Parada; Xuezheng Sun; Chiu-Kit Tse; Andrew F Olshan; Melissa A Troester; Kathleen Conway Journal: Cancer Causes Control Date: 2017-07-10 Impact factor: 2.506
Authors: Nandita Das; Richard N Baumgartner; Elizabeth C Riley; Christina M Pinkston; Dongyan Yang; Kathy B Baumgartner Journal: J Cancer Surviv Date: 2015-04-26 Impact factor: 4.442
Authors: Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash Journal: BMC Neurol Date: 2010-04-12 Impact factor: 2.474
Authors: Antonio Di Meglio; Julie Havas; Arnauld S Gbenou; Elise Martin; Mayssam El-Mouhebb; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Florence Joly; Suzette Delaloge; Patricia A Ganz; Fabrice André; Ann H Partridge; Lee W Jones; Stefan Michiels; Ines Vaz-Luis Journal: J Clin Oncol Date: 2022-04-21 Impact factor: 50.717